Wellcome Trust Centre for Molecular Parasitology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
Hamidou Ilboudo
Centre International de Recherche-Développement sur l'Elevage en zone Subhumide, Bobo-Dioulasso, Burkina Faso; TrypanoGEN, H3Africa Consortium, Makerere University, Kampala, Uganda
V Pius Alibu
TrypanoGEN, H3Africa Consortium, Makerere University, Kampala, Uganda; College of Natural Sciences, Makerere University, Kampala, Uganda
Sophie Ravel
Unité Mixte de Recherche IRD-CIRAD 177, Institut de Recherche pour le Développement, Montpellier, France
John Enyaru
TrypanoGEN, H3Africa Consortium, Makerere University, Kampala, Uganda; College of Natural Sciences, Makerere University, Kampala, Uganda
William Weir
Wellcome Trust Centre for Molecular Parasitology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
Harry Noyes
Wellcome Trust Centre for Molecular Parasitology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom; TrypanoGEN, H3Africa Consortium, Makerere University, Kampala, Uganda; Institute of Integrative Biology, University of Liverpool, Liverpool, United Kingdom
Paul Capewell
Wellcome Trust Centre for Molecular Parasitology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
Mamadou Camara
TrypanoGEN, H3Africa Consortium, Makerere University, Kampala, Uganda; Programme National de Lutte contre la Trypanosomiase Humaine Africaine, Conakry, Guinea
Jacqueline Milet
Unité Mixte de Recherche IRD-CIRAD 177, Institut de Recherche pour le Développement, Montpellier, France
Vincent Jamonneau
Centre International de Recherche-Développement sur l'Elevage en zone Subhumide, Bobo-Dioulasso, Burkina Faso; TrypanoGEN, H3Africa Consortium, Makerere University, Kampala, Uganda; Unité Mixte de Recherche IRD-CIRAD 177, Institut de Recherche pour le Développement, Montpellier, France
Oumou Camara
Programme National de Lutte contre la Trypanosomiase Humaine Africaine, Conakry, Guinea
Enock Matovu
TrypanoGEN, H3Africa Consortium, Makerere University, Kampala, Uganda; College of Veterinary Medicine, Animal Resources and Biosecurity, Makerere University, Kampala, Uganda
Bruno Bucheton
TrypanoGEN, H3Africa Consortium, Makerere University, Kampala, Uganda; Unité Mixte de Recherche IRD-CIRAD 177, Institut de Recherche pour le Développement, Montpellier, France; Programme National de Lutte contre la Trypanosomiase Humaine Africaine, Conakry, Guinea
Wellcome Trust Centre for Molecular Parasitology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom; TrypanoGEN, H3Africa Consortium, Makerere University, Kampala, Uganda
Reduced susceptibility to infectious disease can increase the frequency of otherwise deleterious alleles. In populations of African ancestry, two apolipoprotein-L1 (APOL1) variants with a recessive kidney disease risk, named G1 and G2, occur at high frequency. APOL1 is a trypanolytic protein that confers innate resistance to most African trypanosomes, but not Trypanosoma brucei rhodesiense or T.b. gambiense, which cause human African trypanosomiasis. In this case-control study, we test the prevailing hypothesis that these APOL1 variants reduce trypanosomiasis susceptibility, resulting in their positive selection in sub-Saharan Africa. We demonstrate a five-fold dominant protective association for G2 against T.b. rhodesiense infection. Furthermore, we report unpredicted strong opposing associations with T.b. gambiense disease outcome. G2 associates with faster progression of T.b. gambiense trypanosomiasis, while G1 associates with asymptomatic carriage and undetectable parasitemia. These results implicate both forms of human African trypanosomiasis in the selection and persistence of otherwise detrimental APOL1 kidney disease variants.